These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 23160971)

  • 21. Comparison of average, scaled average, and population bioequivalence methods for assessment of highly variable drugs: an experience with doxifluridine in beagle dogs.
    Baek IH; Lee BY; Kang W; Kwon KI
    Eur J Pharm Sci; 2010 Jan; 39(1-3):175-80. PubMed ID: 19961933
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Variability and impact on design of bioequivalence studies.
    Van Peer A
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):146-53. PubMed ID: 20041877
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Geometric mean ratio-dependent scaled bioequivalence limits with leveling-off properties.
    Karalis V; Macheras P; Symillides M
    Eur J Pharm Sci; 2005 Sep; 26(1):54-61. PubMed ID: 15955680
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of metabolites in bioequivalency assessment. II. Drugs with linear pharmacokinetics and first-pass effect.
    Chen ML; Jackson AJ
    Pharm Res; 1995 May; 12(5):700-8. PubMed ID: 7479556
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of bioequivalence study regulatory requirements for human and veterinary drugs.
    Grabowski T; Marczak M; Jaroszewski JJ; Whitmire M
    Regul Toxicol Pharmacol; 2012 Nov; 64(2):233-42. PubMed ID: 22917973
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Bioequivalence Approach for Generic Narrow Therapeutic Index Drugs: Evaluation of the Reference-Scaled Approach and Variability Comparison Criterion.
    Jiang W; Makhlouf F; Schuirmann DJ; Zhang X; Zheng N; Conner D; Yu LX; Lionberger R
    AAPS J; 2015 Jul; 17(4):891-901. PubMed ID: 25840883
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of non-compartmental and mixed effect modelling methods for establishing bioequivalence for the case of two compartment kinetics and censored concentrations.
    Hughes JH; Upton RN; Foster DJR
    J Pharmacokinet Pharmacodyn; 2017 Jun; 44(3):233-244. PubMed ID: 28194623
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Innovative approaches for demonstration of bioequivalence: the US FDA perspective.
    Zhang X; Zheng N; Lionberger RA; Yu LX
    Ther Deliv; 2013 Jun; 4(6):725-40. PubMed ID: 23738669
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors affecting intrasubject variability of PK exposure: absolute oral bioavailability and acidic nature of drugs.
    Sato M; Narukawa M
    Int J Clin Pharmacol Ther; 2015 Nov; 53(11):955-62. PubMed ID: 26365336
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Harmonization of testing drugs for bioequivalence: problems and possible solutions].
    Zherdev VP; Kolyvanov GB; Litvin AA; Sariev AK
    Eksp Klin Farmakol; 2003; 66(2):60-4. PubMed ID: 12962051
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulatory and study conditions for the determination of bioequivalence of highly variable drugs.
    Endrenyi L; Tothfalusi L
    J Pharm Pharm Sci; 2009; 12(1):138-49. PubMed ID: 19470298
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Estimating product bioequivalence for highly variable veterinary drugs.
    Claxton R; Cook J; Endrenyi L; Lucas A; Martinez MN; Sutton SC
    J Vet Pharmacol Ther; 2012 Apr; 35 Suppl 1():11-6. PubMed ID: 22413787
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inflation of Type I Error in the Evaluation of Scaled Average Bioequivalence, and a Method for its Control.
    Labes D; Schütz H
    Pharm Res; 2016 Nov; 33(11):2805-14. PubMed ID: 27480875
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparing the concentration curves directly in a pharmacokinetics, bioavailability/bioequivalence study.
    Liao JJ
    Stat Med; 2005 Mar; 24(6):883-91. PubMed ID: 15558699
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Computer simulations of bioequivalence trials: selection of design and analyte in BCS drugs with first-pass hepatic metabolism: linear kinetics (I).
    Fernández-Teruel C; Nalda Molina R; González-Alvarez I; Navarro-Fontestad C; García-Arieta A; Casabó VG; Bermejo M
    Eur J Pharm Sci; 2009 Jan; 36(1):137-46. PubMed ID: 19028574
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel bioequivalence approach for narrow therapeutic index drugs.
    Yu LX; Jiang W; Zhang X; Lionberger R; Makhlouf F; Schuirmann DJ; Muldowney L; Chen ML; Davit B; Conner D; Woodcock J
    Clin Pharmacol Ther; 2015 Mar; 97(3):286-91. PubMed ID: 25669762
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of Orally Inhaled Drug Products.
    Hochhaus G; Horhota S; Hendeles L; Suarez S; Rebello J
    AAPS J; 2015 May; 17(3):769-75. PubMed ID: 25762449
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of Bayesian methods for multivariate bioequivalence measures.
    Molina de Souza R; Achcar JA; Martinez EZ
    J Biopharm Stat; 2009; 19(1):42-66. PubMed ID: 19127466
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel scaled average bioequivalence limits based on GMR and variability considerations.
    Karalis V; Symillides M; Macheras P
    Pharm Res; 2004 Oct; 21(10):1933-42. PubMed ID: 15553242
    [TBL] [Abstract][Full Text] [Related]  

  • 40. When are bioavailability studies required? A German proposal.
    Gleiter CH; Klotz U; Kuhlmann J; Blume H; Stanislaus F; Harder S; Paulus H; Poethko-Müller C; Holz-Slomczyk M
    J Clin Pharmacol; 1998 Oct; 38(10):904-11. PubMed ID: 9807970
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.